TMC Pharma Services
TMC Pharma Services is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults with IgA Nephropathy (The BEYOND Study)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors
Sponsor Verastem Inc.
- Start (EU)
- Latest update
- Estimated end
Impact of CardiolRxTM on Recurrent Pericarditis: An open label Pilot Study
Sponsor Cardiol Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Operational learnings available5 trial-level findings · Read insights
- Twenty-seven participants were enrolled across eight US sites between January 9, 2023, and March 4, 2024, with site enrollment ranging from 1 to 9 participants.
- France was not activated because regulatory and ethics approvals were received approximately 6 weeks before the last participant was enrolled.
- Important protocol deviations occurred in 9/27 participants (33.3%), including two inclusion-criteria deviations and two study procedures performed before informed consent.
- Five post-dose ECG timing deviations affected 3 participants.
- One participant missed the C-SSRS questionnaire, and one had repeat blood tests outside the required time window.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203)
Sponsor Verastem Inc.
- Start (EU)
- Latest update
- Estimated end
A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY TO DETERMINE THE SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN PARTICIPANTS WITH SEVERE, REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS WITH ACTIVE LUPUS NEPHRITIS
Sponsor Autolus Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
IMpAct of CardiolRxTM oVer 6 months following IL-1 Blocker cessation in pERICarditis patients – MAVERIC: A randomized, double-blind, placebo-controlled trial
Sponsor Cardiol Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodect in Adult and Adolescent Patients with Tourette Syndrome – Allevia 2
Sponsor Noema Pharma AG
- Start (EU)
- Latest update
- Estimated end
A 52-Week, Open-Label Evaluation of the Long-term Efficacy and Safety of Single and Repeated Treatments with Methylone for the Treatment of PTSD IMPACT-EXT (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])
Sponsor Transcend Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
“Impact of CardiolRx on Myocardial Recovery in patients with Acute Myocarditis. A double-blind, placebo-controlled trial (ARCHER)”
Sponsor Cardiol Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for TMC Pharma Services?
The 2026-10-09 snapshot links TMC Pharma Services to 9 distinct CTIS trials. Recorded services include Regulatory services, Safety reporting & pharmacovigilance, Clinical monitoring, Investigator recruitment, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for TMC Pharma Services?
The most frequently recorded therapeutic areas are Cardiology, Gastroenterology, Gynecology, Hepatology. Recorded phases include Phase 1, Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to TMC Pharma Services conducted?
The linked trials record locations in 12 countries, including France, Belgium, Spain, Germany, Greece. These are trial locations, not confirmed office locations or countries where TMC Pharma Services delivered services.
What can this page tell me about TMC Pharma Services's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under TMC Pharma Services. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- TMC Pharma Services Limited